報告摘要

The global Antibody-drug Conjugate for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032. North America: the Antibody-drug Conjugate for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antibody-drug Conjugate for Cancer market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antibody-drug Conjugate for Cancer market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antibody-drug Conjugate for Cancer include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda. among others; in 2025, the top three vendors together accounted for approximately % of global revenue. Report Scope This report quantifies the global Antibody-drug Conjugate for Cancer market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody-drug Conjugate for Cancer. Key Companies & Market Share Insights This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Antibody-drug Conjugate for Cancer Market by Company Gilead Sciences Innate Pharma Rakuten Medical Seagen AstraZeneca GSK Pfizer Roche Takeda Antibody-drug Conjugate for Cancer Segment by Type Hematological Malignancies Drugs Solid Tumor Drugs Antibody-drug Conjugate for Cancer Segment by Application Hospital Pharmacy Other Antibody-drug Conjugate for Cancer Segment by Region North America United States Canada Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer. 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report.

目錄 Table of Contents

1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Antibody-drug Conjugate for Cancer by Type 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) 2.2.2 Hematological Malignancies Drugs 2.2.3 Solid Tumor Drugs 2.3 Antibody-drug Conjugate for Cancer by Application 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.3.2 Hospital 2.3.3 Pharmacy 2.3.4 Other 2.4 Assumptions and Limitations 3 Antibody-drug Conjugate for Cancer Breakdown Data by Type 3.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2021-2026) 3.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2027-2032) 4 Antibody-drug Conjugate for Cancer Breakdown Data by Application 4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2021-2026) 4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2027-2032) 5 Global Growth Trends 5.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2021-2032) 5.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region 5.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2021 VS 2025 VS 2032 5.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2021-2026) 5.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2027-2032) 5.3 Antibody-drug Conjugate for Cancer Market Dynamics 5.3.1 Antibody-drug Conjugate for Cancer Industry Trends 5.3.2 Antibody-drug Conjugate for Cancer Market Drivers 5.3.3 Antibody-drug Conjugate for Cancer Market Challenges 5.3.4 Antibody-drug Conjugate for Cancer Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue 6.1.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue (2021-2026) 6.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2021-2026) 6.2 Global Antibody-drug Conjugate for Cancer Industry Players Ranking, 2023 VS 2024 VS 2025 6.3 Global Key Players of Antibody-drug Conjugate for Cancer Head Office and Area Served 6.4 Global Antibody-drug Conjugate for Cancer Players, Product Type & Application 6.5 Global Antibody-drug Conjugate for Cancer Manufacturers Established Date 6.6 Global Antibody-drug Conjugate for Cancer Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Antibody-drug Conjugate for Cancer Market Size (2021-2032) 7.2 North America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 7.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) 7.4 North America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) 7.5 United States 7.5 United States 7.6 Canada 7.7 Mexico 8 Europe 8.1 Europe Antibody-drug Conjugate for Cancer Market Size (2021-2032) 8.2 Europe Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 8.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) 8.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) 8.5 Germany 8.6 France 8.7 U.K. 8.8 Italy 8.9 Spain 8.10 Russia 8.11 Netherlands 8.12 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size (2021-2032) 9.2 Asia-Pacific Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 9.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) 9.4 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) 9.5 China 9.6 Japan 9.7 South Korea 9.8 India 9.9 Australia 9.10 China Taiwan 9.11 Southeast Asia 10 South America 10.1 South America Antibody-drug Conjugate for Cancer Market Size (2021-2032) 10.2 South America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 10.3 South America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) 10.4 South America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) 10.5 Brazil 10.6 Argentina 10.7 Chile 10.8 Colombia 10.9 Peru 11 Middle East & Africa 11.1 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2021-2032) 11.2 Middle East & Africa Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 11.3 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) 11.4 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) 11.5 Saudi Arabia 11.6 Israel 11.7 United Arab Emirates 11.8 Turkey 11.9 Iran 11.10 Egypt 12 Players Profiled 12.1 Gilead Sciences 12.1.1 Gilead Sciences Company Information 12.1.2 Gilead Sciences Business Overview 12.1.3 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio 12.1.5 Gilead Sciences Recent Developments 12.2 Innate Pharma 12.2.1 Innate Pharma Company Information 12.2.2 Innate Pharma Business Overview 12.2.3 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio 12.2.5 Innate Pharma Recent Developments 12.3 Rakuten Medical 12.3.1 Rakuten Medical Company Information 12.3.2 Rakuten Medical Business Overview 12.3.3 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio 12.3.5 Rakuten Medical Recent Developments 12.4 Seagen 12.4.1 Seagen Company Information 12.4.2 Seagen Business Overview 12.4.3 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio 12.4.5 Seagen Recent Developments 12.5 AstraZeneca 12.5.1 AstraZeneca Company Information 12.5.2 AstraZeneca Business Overview 12.5.3 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio 12.5.5 AstraZeneca Recent Developments 12.6 GSK 12.6.1 GSK Company Information 12.6.2 GSK Business Overview 12.6.3 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio 12.6.5 GSK Recent Developments 12.7 Pfizer 12.7.1 Pfizer Company Information 12.7.2 Pfizer Business Overview 12.7.3 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio 12.7.5 Pfizer Recent Developments 12.8 Roche 12.8.1 Roche Company Information 12.8.2 Roche Business Overview 12.8.3 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio 12.8.5 Roche Recent Developments 12.9 Takeda 12.9.1 Takeda Company Information 12.9.2 Takeda Business Overview 12.9.3 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) 12.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio 12.9.5 Takeda Recent Developments 13 Report Conclusion 14 Disclaimer

圖表清單 List of Tables & Figures

List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2026) Table 7. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2027-2032) Table 9. Global Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2026) Table 11. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2027-2032) Table 13. Global Antibody-drug Conjugate for Cancer Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antibody-drug Conjugate for Cancer Market Share by Region (2021-2026) Table 16. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antibody-drug Conjugate for Cancer Market Share by Region (2027-2032) Table 18. Antibody-drug Conjugate for Cancer Industry Trends Table 19. Antibody-drug Conjugate for Cancer Industry Drivers Table 20. Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges Table 21. Antibody-drug Conjugate for Cancer Market Restraints Table 22. Global Top Antibody-drug Conjugate for Cancer Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2021-2026) Table 24. Global Antibody-drug Conjugate for Cancer Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Antibody-drug Conjugate for Cancer, Headquarters and Area Served Table 26. Global Antibody-drug Conjugate for Cancer Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Antibody-drug Conjugate for Cancer by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) & (US$ Million) Table 45. Gilead Sciences Company Information Table 46. Gilead Sciences Business Overview Table 47. Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 48. Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio Table 49. Gilead Sciences Recent Developments Table 50. Innate Pharma Company Information Table 51. Innate Pharma Business Overview Table 52. Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 53. Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio Table 54. Innate Pharma Recent Developments Table 55. Rakuten Medical Company Information Table 56. Rakuten Medical Business Overview Table 57. Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 58. Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio Table 59. Rakuten Medical Recent Developments Table 60. Seagen Company Information Table 61. Seagen Business Overview Table 62. Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 63. Seagen Antibody-drug Conjugate for Cancer Product Portfolio Table 64. Seagen Recent Developments Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 68. AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio Table 69. AstraZeneca Recent Developments Table 70. GSK Company Information Table 71. GSK Business Overview Table 72. GSK Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 73. GSK Antibody-drug Conjugate for Cancer Product Portfolio Table 74. GSK Recent Developments Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 78. Pfizer Antibody-drug Conjugate for Cancer Product Portfolio Table 79. Pfizer Recent Developments Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 83. Roche Antibody-drug Conjugate for Cancer Product Portfolio Table 84. Roche Recent Developments Table 85. Takeda Company Information Table 86. Takeda Business Overview Table 87. Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026) & (US$ Million) Table 88. Takeda Antibody-drug Conjugate for Cancer Product Portfolio Table 89. Takeda Recent Developments Table 90. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antibody-drug Conjugate for Cancer Product Image Figure 5. Global Antibody-drug Conjugate for Cancer Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Antibody-drug Conjugate for Cancer Market Share by Type: 2025 VS 2032 Figure 7. Hematological Malignancies Drugs Product Figure 8. Solid Tumor Drugs Product Figure 9. Global Antibody-drug Conjugate for Cancer Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antibody-drug Conjugate for Cancer Market Share by Application: 2025 VS 2032 Figure 11. Hospital Product Figure 12. Pharmacy Product Figure 13. Other Product Figure 14. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Antibody-drug Conjugate for Cancer Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2025 VS 2032 Figure 17. Global Antibody-drug Conjugate for Cancer Market Share by Players in 2025 Figure 18. Global Antibody-drug Conjugate for Cancer Manufacturers Established Date Figure 19. Global Top 5 and 10 Antibody-drug Conjugate for Cancer Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 23. United States Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 26. Europe Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 28. Germany Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 38. China Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 43. Australia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 48. Brazil Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Antibody-drug Conjugate for Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Gilead Sciences Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 54. Innate Pharma Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 55. Rakuten Medical Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 56. Seagen Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 57. AstraZeneca Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 58. GSK Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 59. Pfizer Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 60. Roche Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026) Figure 61. Takeda Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2021-2026)

Single User	$2,950 USD
Multi User	$4,430 USD
Enterprise	$5,900 USD

Antibody-drug Conjugate for Cancer Industry Research Report 2026

授權報價

報告摘要

提及公司